Publications by authors named "David Salinger"

Claim this Profile
R
Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy.
Samira Merali, David H Salinger, Maria Palmisano, Amy J Sehnert, Neelima Thanneer

CPT Pharmacometrics Syst Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration.
Peter Chang, Vidya Perera, David H Salinger, Samira Merali, Neelima Thanneer

CPT Pharmacometrics Syst Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence of Human-Level Bonds Established With a Digital Conversational Agent: Cross-sectional, Retrospective Observational Study.
Alison Darcy, Jade Daniels, David Salinger, Paul Wicks, Athena Robinson

JMIR Form Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Exposure-Response Perspective on the Clinical Dose of Pretomanid.
Jerry R Nedelman, David H Salinger, Vishak Subramoney, Rob Woolson, Karen Wade

Antimicrob Agents Chemother· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daily Dosing for Bedaquiline in Patients with Tuberculosis.
David H Salinger, Jerry R Nedelman, Carl Mendel, Melvin Spigelman, David J Hermann

Antimicrob Agents Chemother· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Hanbin Li, David H Salinger, Daniel Everitt, Mengchun Li, Angelo Del Parigi

Antimicrob Agents Chemother· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.
David H Salinger, Vishak Subramoney, Daniel Everitt, Jerry R Nedelman

Antimicrob Agents Chemother· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseases.
Hong Li, Kathleen Köck, John A Wisler, William A Rees, Peter J Prince, David H Salinger

Pharmacol Res Perspect· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.
Jeannine S McCune, Paolo Vicini, David H Salinger, Paul V O'Donnell, Brenda M Sandmaier

Cancer Chemother Pharmacol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.
Christopher J Endres, David H Salinger, Kathleen Köck, Marc R Gastonguay, David A Martin

J Clin Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
David H Salinger, Christopher J Endres, David A Martin, Megan A Gibbs

Clin Pharmacol Drug Dev· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.
Chris B Russell, Hugh Rand, Jeannette Bigler, Keith Kerkof, Martin Timour, David H Salinger

J Immunol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.
David A Martin, Melvin Churchill, Luis Flores-Suarez, Mario H Cardiel, Daniel Wallace, David Salinger

Arthritis Res Ther· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients.
Hong Li, Donald E Mager, Meagan J Bemer, David H Salinger, Paolo Vicini

J Clin Pharmacol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.
Kim A Papp, Cathy Reid, Peter Foley, Rod Sinclair, David H Salinger

J Invest Dermatol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
Jennifer Q Dong, David H Salinger, Christopher J Endres, John P Gibbs, Cheng-Pang Hsu

Clin Pharmacokinet· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
David H Salinger, Paolo Vicini, David K Blough, Paul V O'Donnell, Matthew A Pawlikowski

J Clin Pharmacol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurement of human surfactant protein-B turnover in vivo from tracheal aspirates using targeted proteomics.
Daniela M Tomazela, Bruce W Patterson, Elizabeth Hanson, Kimberly L Spence, Tiffany B Kanion, David H Salinger

Anal Chem· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.
David H Salinger, Danny D Shen, Kenneth Thummel, Ann K Wittkowsky, Paolo Vicini

Pharmacogenet Genomics· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.
David H Salinger, David K Blough, Paolo Vicini, Claudio Anasetti, Paul V O'Donnell

Clin Cancer Res· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration.
Meng Li, Marilee A Andrew, Joanne Wang, David H Salinger, Paolo Vicini

Antimicrob Agents Chemother· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.
Jeannine S McCune, David H Salinger, Paolo Vicini, Celeste Oglesby, David K Blough

J Clin Pharmacol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics.
Anne M Lynn, Heidi Bradford, Eric D Kantor, Kok-Yong Seng, David H Salinger

Anesth Analg· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach.
David H Salinger, Jeannine S McCune, Aaron G Ren, Danny D Shen, John T Slattery

Clin Cancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis